Emerging role of multikinase inhibitors for refractory thyroid cancer Full Text
Biologics: targets & therapy, 08/21/2012
Perez CA et al. – With the approval of vandetanib for the treatment of medullary thyroid cancer, a new era in the management of this disease has begun. The molecular rationale for the use of these drugs for thyroid cancer is discussed as well as their promising clinical results.